Celgene Corp (CELGZ) 2.57 $CELGZ
Global Neuroblastoma Clinical Trials Review 2014 - Analysis of 9 Companies
M2 - Wed Apr 16, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfcrvd/neuroblastoma) has announced the addition of the "Neuroblastoma Global Clinical Trials Review, H1, 2014" report to their offering. Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials - Progenics Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - APEIRON Biologics AG - United Therapeutics Corporation - Cancer Prevention Pharmaceuticals, Inc. - MabVax Therapeutics, Inc. - Eli Lilly and Company - Celgene Corporation - Biotec Pharmacon ASA For more information visit http://www.researchandmarkets.com/research/hf...roblastoma
Global Malignant Glioma Clinical Trials Review 2014
M2 - Tue Apr 15, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jwz85/malignant_glioma) has announced the addition of the "Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - Insys Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Sanofi - Tactical Therapeutics, Inc - GlaxoSmithKline plc - Celgene Corporation - Amgen Inc. - Advantagene, Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - UCLA's Jonsson Comprehensive Cancer Center - Northwestern University - NCIC Clinical Trials Group - European Organization for Research and Treatment of Cancer For more information visit http://www.researchandmarkets.com/research/5j...ant_glioma
ReCept Pharmacy to Distribute Otezla® (apremilast): The First FDA Approved Oral Medication for the Treatment of Psoriatic Arthritis for Adults
PR Newswire - Mon Apr 14, 4:45PM CDT
ReCept announces that it is among a select group of specialty pharmacies selected by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule which works by blocking the enzyme phosphodiesterase 4 to reduce swelling in joints and improve physical function in a form of arthritis that afflicts psoriasis sufferers. Approved by the FDA on March 21, 2014 and available for dispensing on April 9, ReCept has immediate access to dispense Otezla® at initial launch.
Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health Sciences Inc. (NYSE: USNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1050-100free
Global B-Cell Non-Hodgkin Lymphoma Clinical Trials Review
M2 - Thu Apr 10, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5nm9/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Takeda Pharmaceutical Company Limited - GlaxoSmithKline plc - Amgen Inc. - Novartis AG - Pharmacyclics, Inc. - Pfizer Inc. - Biogen Idec Inc. - Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Mayo Clinic - Southwest Oncology Group - Groupe d'Etudes de Lymphomes de L'Adulte - City of Hope National Medical Center - Stanford University For more information visit http://www.researchandmarkets.com/research/6w5nm9/bcell
BlackBerry CEO May Consider Exiting Handset Business; Celgene Corporation Favored over Natco in Pre-trial
ACCESSWIRE - Wed Apr 09, 11:43PM CDT
Merck & Co. Inc. (NYSE: MRK) - For an in-depth report on Merck & Co. Inc. follow: www.BullTrends.com/stockquote/MRK
Pancreatic Cancer Sales to Rise to USD 1.63 Bn in the US and 5EU, According to GlobalData Report Published at MarketPublishers.com
PRWeb - Wed Apr 09, 1:10PM CDT
The pancreatic cancer market value in the US and 5EU (the six major markets, or 6MM) in 2012 was USD 529 million. Just over 50% of pancreatic cancer sales (USD 275 million) were generated in the US, while sales in the 5EU stood at USD 254 million. By 2017-end, pancreatic cancer sales are projected to rise to USD 1.63 billion in the US and 5EU, at a CAGR of just over 25%. The proportion of sales from the US is expected to increase to 72%, whilst market share in the 5EU is set to decrease to 28% by the end of the forecast period. The market size is predicted to undergo a tremendous and fast increase across the US and 5EU owing to the launch of Celgene's Abraxane and the incorporation of five agents in the pipeline into US clinical practice in the offing. The sales of Abraxane are forecast to represent about 60% of the pancreatic cancer marketplace by the end of the forecast period, growing at a CAGR of 115% to reach USD 954 million in 2017.
Global Metastatic Breast Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zsqx35/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Breast Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Breast Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Metastatic Breast Cancer Therapeutics Clinical Trials - F. Hoffmann-La Roche Ltd. - Novartis AG - GlaxoSmithKline plc - Eli Lilly and Company - AstraZeneca PLC - Pfizer Inc. - Sanofi - Bristol-Myers Squibb Company - Johnson & Johnson - Celgene Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Sarah Cannon Research Institute - North Central Cancer Treatment Group - European Organization for Research and Treatment of Cancer - FUDAN University - UCLA's Jonsson Comprehensive Cancer Center - Vanderbilt-Ingram Cancer Center Visit http://www.researchandmarkets.com/research/zs...tic_breast
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL BioPharma, and Hemispherx Biopharma
PR Newswire - Tue Apr 08, 12:20PM CDT
On Monday, April 07, 2014, the NASDAQ Composite ended at 4,079.75, down 1.16%, the Dow Jones Industrial Average finished the session 1.02% lower at 16,245.87, and the S&P 500 closed at 1,845.04, down 1.08%. The losses were broad based as nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index finished the day 1.06% lower at 664.68, while the same has gained 3.19% in the previous three months. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corp. (NASDAQ: CELG), PDL BioPharma Inc. (NASDAQ: PDLI) and Hemispherx Biopharma Inc. (NYSE MKT: HEB). Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at:
Conference Call Schedules, Clinical Trial Studies, Awards and Accolades, Appointments, and Welfare Initiatives - Analyst Notes on Celgene, Johnson & Johnson, Merck, Sanofi, and UnitedHealth
PR Newswire - Tue Apr 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Sanofi (NYSE: SNY), and UnitedHealth Group, Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pharma Opportunity/Analyzer Report: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017
M2 - Mon Apr 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59k64h/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017" report to their offering. New Drug Launches Will Drive Rapid Growth in the US and EU Pancreatic Cancer Market from 2012-2017 The authors estimates that the value of the pancreatic cancer market in the US and 5EU (France, Germany, Italy, Spain, and the UK) in 2012 was $529m. This market is defined as sales of branded drugs and major generic regimens commonly prescribed for pancreatic cancer patients across the six major markets (6MM). Just over half of these sales, $275m (52%), were generated in the US, while sales in the 5EU were estimated at $254m (48%). By 2017, the end of the forecast period, The authors projects pancreatic cancer sales to rise to $1.63 billion in the US and 5EU, at a high Compound Annual Growth Rate (CAGR) of 25.2%. The authors expects the proportion of sales from the US to increase to 72%, with market share in the 5EU decreasing to 28% by 2017. The overall rapid increase in the market size across the 6MM is attributed to the launch of Celgene's Abraxane in 2013 in the US and 2014 in Europe, and the incorporation of five pipeline agents into US clinical practice by the end of the forecast period. The authors forecasts sales of Abraxane to rise significantly, from $21m in 2012 to $954m in 2017, at a CAGR of 115%; sales of Abraxane will represent nearly 60% of the pancreatic cancer market by the end of the forecast period. Major drivers of the pancreatic cancer market in the US and 5EU during the forecast period include the following: - The greatest driver of the pancreatic cancer market across the 6MM will be the strong and rapid adoption of premium-priced Abraxane in place of generic chemotherapy regimens, such as FOLFIRINOX (5-flourouracil [5-FU]/leucovorin/irinotecan/oxaliplatin) and gemcitabine monotherapy. The authors forecasts particularly strong growth in the US, the largest market for pancreatic cancer therapeutics, and the market where Abraxane is priced the highest. - Of the five new pipeline agents that will be launched during the forecast period, NewLink Genetics Corporation's algenpantucel-L is expected to garner the highest sales, and is expected to launch in both the resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck's TH-302, and Merrimack Pharmaceuticals' MM-398. - The incidence of pancreatic cancer is increasing across the 6MM, resulting in further treatment opportunities for premium-priced therapeutics. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Opportunity Analysis 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/59...ityanalyze
Celgene Corporation Sued by Mylan Inc.; GRUBHUB Soars on its First Day of Trading
ACCESSWIRE - Sun Apr 06, 11:10PM CDT
GRUBHUB INC. (NYSE: GRUB) - For an in-depth report on GRUBHUB INC. follow: www.BullTrends.com/stockquote/GRUB
BetterInvesting Magazine Releases June Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri Apr 04, 3:15PM CDT
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Skyworks Solutions, Inc. (NDQ: SWKS) as its June 2014 "Stock to Study" and Celgene Corporation (NDQ: CELG) as its June 2014 "Undervalued Stock" for investors' informational and educational use.
Launch of Additional First- and Second-Line Options Will Substantially Expand the Treatment Landscape for Myelodysplastic Syndromes Through 2023
PR Newswire - Thu Apr 03, 10:00AM CDT
Decision Resources Group finds that azacitidine (Celgene's Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to clinical trial data and expert opinion, treatment options for MDS will expand significantly over the next decade with the launches of as many as five novel therapies: Cyclacel's sapacitabine, Mirati Therapeutics' mocetinostat, Celgene's oral azacitidine, Onconova's oral rigosertib and Acceleron/Celgene's sotatercept, as well as a label extension for GlaxoSmithKline's Revolade/Promacta.
Healthcare Companies Report Transactions, Appeals, New Research Findings and Stock Movements - Analyst Notes on Johnson & Johnson, Teva, Celgene, Cara Therapeutics, and OncoMed Pharmaceuticals
PR Newswire - Thu Apr 03, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Celgene Corporation (NASDAQ: CELG), Cara Therapeutics Inc. (NASDAQ: CARA), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Critical Alerts For News Corp, Gold SPDR, McDonalds, Trina Solar, and Celgene Released By InvestorsObserver
PR Newswire - Tue Apr 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for NWSA, GLD, MCD, TSL, and CELG.
Celgene Corporation to Announce First Quarter 2014 Results on April 24, 2014
Business Wire - Tue Apr 01, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 24, 2014 at 9 a.m. ET to discuss first quarter 2014 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com.
FORMA Therapeutics and Celgene Corporation Announce a Novel and Expansive Multi-Year Strategic Alliance
Business Wire - Tue Apr 01, 6:30AM CDT
--FORMA controls projects through early clinical development and retains U.S. rights to all products
APAC Non-Small Cell Lung Cancer Market to Post 6.3% CAGR Through 2019, States GBI Research in Its Report Published at MarketPublishers.com
PRWeb - Mon Mar 31, 1:05PM CDT
As for 2012, the non-small cell lung cancer (NSCLC) market in the APAC region was evaluated at around USD 1.8 billion. By 2019, the region's market is predicted to post a 6.3% CAGR to amount to USD 2.9 billion. The major drivers of the APAC NSCLC market growth include a rapidly ageing population, a rising prevalence of NSCLC cases, and the expected introduction of promising therapies. Through 2019, the APAC NSCLC market is anticipated to be driven by the launch of high-price novel immunotherapies and antibodies in the 1st and 2nd therapy lines, including Pfizer's dacomitinib, Novartis's LDK378, Bristol-Myers Squibb's Yervoy nivolumab and (ipilimumab), Eli Lilly's necitumumab and also Boehringer Ingelheim's Gilotrif. However, the recent adoption of a price ceiling on essential drugs, planned pricing restrictions in Chinaб and also dominance of generic drugs in the Indian market could pose a significant challenge to the APAC NSCLC market growth.
Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A
M2 - Mon Mar 31, 4:25AM CDT
The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity in pursuing this therapy area - Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.
Global Neuroblastoma Clinical Trials Review 2014 - Analysis of 9 Companies
M2 - Wed Apr 16, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfcrvd/neuroblastoma) has announced the addition of the "Neuroblastoma Global Clinical Trials Review, H1, 2014" report to their offering. Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials - Progenics Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - APEIRON Biologics AG - United Therapeutics Corporation - Cancer Prevention Pharmaceuticals, Inc. - MabVax Therapeutics, Inc. - Eli Lilly and Company - Celgene Corporation - Biotec Pharmacon ASA For more information visit http://www.researchandmarkets.com/research/hf...roblastoma
Global Malignant Glioma Clinical Trials Review 2014
M2 - Tue Apr 15, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jwz85/malignant_glioma) has announced the addition of the "Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - Insys Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Sanofi - Tactical Therapeutics, Inc - GlaxoSmithKline plc - Celgene Corporation - Amgen Inc. - Advantagene, Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - UCLA's Jonsson Comprehensive Cancer Center - Northwestern University - NCIC Clinical Trials Group - European Organization for Research and Treatment of Cancer For more information visit http://www.researchandmarkets.com/research/5j...ant_glioma
ReCept Pharmacy to Distribute Otezla® (apremilast): The First FDA Approved Oral Medication for the Treatment of Psoriatic Arthritis for Adults
PR Newswire - Mon Apr 14, 4:45PM CDT
ReCept announces that it is among a select group of specialty pharmacies selected by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule which works by blocking the enzyme phosphodiesterase 4 to reduce swelling in joints and improve physical function in a form of arthritis that afflicts psoriasis sufferers. Approved by the FDA on March 21, 2014 and available for dispensing on April 9, ReCept has immediate access to dispense Otezla® at initial launch.
Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health Sciences Inc. (NYSE: USNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1050-100free
Global B-Cell Non-Hodgkin Lymphoma Clinical Trials Review
M2 - Thu Apr 10, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5nm9/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Takeda Pharmaceutical Company Limited - GlaxoSmithKline plc - Amgen Inc. - Novartis AG - Pharmacyclics, Inc. - Pfizer Inc. - Biogen Idec Inc. - Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Mayo Clinic - Southwest Oncology Group - Groupe d'Etudes de Lymphomes de L'Adulte - City of Hope National Medical Center - Stanford University For more information visit http://www.researchandmarkets.com/research/6w5nm9/bcell
BlackBerry CEO May Consider Exiting Handset Business; Celgene Corporation Favored over Natco in Pre-trial
ACCESSWIRE - Wed Apr 09, 11:43PM CDT
Merck & Co. Inc. (NYSE: MRK) - For an in-depth report on Merck & Co. Inc. follow: www.BullTrends.com/stockquote/MRK
Pancreatic Cancer Sales to Rise to USD 1.63 Bn in the US and 5EU, According to GlobalData Report Published at MarketPublishers.com
PRWeb - Wed Apr 09, 1:10PM CDT
The pancreatic cancer market value in the US and 5EU (the six major markets, or 6MM) in 2012 was USD 529 million. Just over 50% of pancreatic cancer sales (USD 275 million) were generated in the US, while sales in the 5EU stood at USD 254 million. By 2017-end, pancreatic cancer sales are projected to rise to USD 1.63 billion in the US and 5EU, at a CAGR of just over 25%. The proportion of sales from the US is expected to increase to 72%, whilst market share in the 5EU is set to decrease to 28% by the end of the forecast period. The market size is predicted to undergo a tremendous and fast increase across the US and 5EU owing to the launch of Celgene's Abraxane and the incorporation of five agents in the pipeline into US clinical practice in the offing. The sales of Abraxane are forecast to represent about 60% of the pancreatic cancer marketplace by the end of the forecast period, growing at a CAGR of 115% to reach USD 954 million in 2017.
Global Metastatic Breast Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zsqx35/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Breast Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Breast Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Metastatic Breast Cancer Therapeutics Clinical Trials - F. Hoffmann-La Roche Ltd. - Novartis AG - GlaxoSmithKline plc - Eli Lilly and Company - AstraZeneca PLC - Pfizer Inc. - Sanofi - Bristol-Myers Squibb Company - Johnson & Johnson - Celgene Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Sarah Cannon Research Institute - North Central Cancer Treatment Group - European Organization for Research and Treatment of Cancer - FUDAN University - UCLA's Jonsson Comprehensive Cancer Center - Vanderbilt-Ingram Cancer Center Visit http://www.researchandmarkets.com/research/zs...tic_breast
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL BioPharma, and Hemispherx Biopharma
PR Newswire - Tue Apr 08, 12:20PM CDT
On Monday, April 07, 2014, the NASDAQ Composite ended at 4,079.75, down 1.16%, the Dow Jones Industrial Average finished the session 1.02% lower at 16,245.87, and the S&P 500 closed at 1,845.04, down 1.08%. The losses were broad based as nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index finished the day 1.06% lower at 664.68, while the same has gained 3.19% in the previous three months. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corp. (NASDAQ: CELG), PDL BioPharma Inc. (NASDAQ: PDLI) and Hemispherx Biopharma Inc. (NYSE MKT: HEB). Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at:
Conference Call Schedules, Clinical Trial Studies, Awards and Accolades, Appointments, and Welfare Initiatives - Analyst Notes on Celgene, Johnson & Johnson, Merck, Sanofi, and UnitedHealth
PR Newswire - Tue Apr 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Sanofi (NYSE: SNY), and UnitedHealth Group, Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pharma Opportunity/Analyzer Report: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017
M2 - Mon Apr 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59k64h/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017" report to their offering. New Drug Launches Will Drive Rapid Growth in the US and EU Pancreatic Cancer Market from 2012-2017 The authors estimates that the value of the pancreatic cancer market in the US and 5EU (France, Germany, Italy, Spain, and the UK) in 2012 was $529m. This market is defined as sales of branded drugs and major generic regimens commonly prescribed for pancreatic cancer patients across the six major markets (6MM). Just over half of these sales, $275m (52%), were generated in the US, while sales in the 5EU were estimated at $254m (48%). By 2017, the end of the forecast period, The authors projects pancreatic cancer sales to rise to $1.63 billion in the US and 5EU, at a high Compound Annual Growth Rate (CAGR) of 25.2%. The authors expects the proportion of sales from the US to increase to 72%, with market share in the 5EU decreasing to 28% by 2017. The overall rapid increase in the market size across the 6MM is attributed to the launch of Celgene's Abraxane in 2013 in the US and 2014 in Europe, and the incorporation of five pipeline agents into US clinical practice by the end of the forecast period. The authors forecasts sales of Abraxane to rise significantly, from $21m in 2012 to $954m in 2017, at a CAGR of 115%; sales of Abraxane will represent nearly 60% of the pancreatic cancer market by the end of the forecast period. Major drivers of the pancreatic cancer market in the US and 5EU during the forecast period include the following: - The greatest driver of the pancreatic cancer market across the 6MM will be the strong and rapid adoption of premium-priced Abraxane in place of generic chemotherapy regimens, such as FOLFIRINOX (5-flourouracil [5-FU]/leucovorin/irinotecan/oxaliplatin) and gemcitabine monotherapy. The authors forecasts particularly strong growth in the US, the largest market for pancreatic cancer therapeutics, and the market where Abraxane is priced the highest. - Of the five new pipeline agents that will be launched during the forecast period, NewLink Genetics Corporation's algenpantucel-L is expected to garner the highest sales, and is expected to launch in both the resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck's TH-302, and Merrimack Pharmaceuticals' MM-398. - The incidence of pancreatic cancer is increasing across the 6MM, resulting in further treatment opportunities for premium-priced therapeutics. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Opportunity Analysis 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/59...ityanalyze
Celgene Corporation Sued by Mylan Inc.; GRUBHUB Soars on its First Day of Trading
ACCESSWIRE - Sun Apr 06, 11:10PM CDT
GRUBHUB INC. (NYSE: GRUB) - For an in-depth report on GRUBHUB INC. follow: www.BullTrends.com/stockquote/GRUB
BetterInvesting Magazine Releases June Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri Apr 04, 3:15PM CDT
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Skyworks Solutions, Inc. (NDQ: SWKS) as its June 2014 "Stock to Study" and Celgene Corporation (NDQ: CELG) as its June 2014 "Undervalued Stock" for investors' informational and educational use.
Launch of Additional First- and Second-Line Options Will Substantially Expand the Treatment Landscape for Myelodysplastic Syndromes Through 2023
PR Newswire - Thu Apr 03, 10:00AM CDT
Decision Resources Group finds that azacitidine (Celgene's Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to clinical trial data and expert opinion, treatment options for MDS will expand significantly over the next decade with the launches of as many as five novel therapies: Cyclacel's sapacitabine, Mirati Therapeutics' mocetinostat, Celgene's oral azacitidine, Onconova's oral rigosertib and Acceleron/Celgene's sotatercept, as well as a label extension for GlaxoSmithKline's Revolade/Promacta.
Healthcare Companies Report Transactions, Appeals, New Research Findings and Stock Movements - Analyst Notes on Johnson & Johnson, Teva, Celgene, Cara Therapeutics, and OncoMed Pharmaceuticals
PR Newswire - Thu Apr 03, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Celgene Corporation (NASDAQ: CELG), Cara Therapeutics Inc. (NASDAQ: CARA), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Critical Alerts For News Corp, Gold SPDR, McDonalds, Trina Solar, and Celgene Released By InvestorsObserver
PR Newswire - Tue Apr 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for NWSA, GLD, MCD, TSL, and CELG.
Celgene Corporation to Announce First Quarter 2014 Results on April 24, 2014
Business Wire - Tue Apr 01, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 24, 2014 at 9 a.m. ET to discuss first quarter 2014 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com.
FORMA Therapeutics and Celgene Corporation Announce a Novel and Expansive Multi-Year Strategic Alliance
Business Wire - Tue Apr 01, 6:30AM CDT
--FORMA controls projects through early clinical development and retains U.S. rights to all products
APAC Non-Small Cell Lung Cancer Market to Post 6.3% CAGR Through 2019, States GBI Research in Its Report Published at MarketPublishers.com
PRWeb - Mon Mar 31, 1:05PM CDT
As for 2012, the non-small cell lung cancer (NSCLC) market in the APAC region was evaluated at around USD 1.8 billion. By 2019, the region's market is predicted to post a 6.3% CAGR to amount to USD 2.9 billion. The major drivers of the APAC NSCLC market growth include a rapidly ageing population, a rising prevalence of NSCLC cases, and the expected introduction of promising therapies. Through 2019, the APAC NSCLC market is anticipated to be driven by the launch of high-price novel immunotherapies and antibodies in the 1st and 2nd therapy lines, including Pfizer's dacomitinib, Novartis's LDK378, Bristol-Myers Squibb's Yervoy nivolumab and (ipilimumab), Eli Lilly's necitumumab and also Boehringer Ingelheim's Gilotrif. However, the recent adoption of a price ceiling on essential drugs, planned pricing restrictions in Chinaб and also dominance of generic drugs in the Indian market could pose a significant challenge to the APAC NSCLC market growth.
Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A
M2 - Mon Mar 31, 4:25AM CDT
The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity in pursuing this therapy area - Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.
